What's on

  • November 30, 2017

    IDIBAPS hosts the annual meeting of the European AIDS Vaccine Initiative (EAVI2020)

    At the beginning of November, scientists from 22 institutions in Europe, Australia, Canada and the United States, which are part of the European AIDS Vaccine Initiative 2020 (EAVI2020), met in Barcelona to analyze the latest advances in the development of an effective vaccine against HIV within the framework of the European Research and Development Program Horizon 2020. The three Spanish centers participating in this consortium are the IDIBAPS, organizer of the meeting, the IrsiCaixa AIDS Research Institute and the Institute of Health Carlos III. In the context of the meeting a photo exhibition entitled "The development of an HIV vaccine in photos" was presented, with the aim of sharing the scientific advances at the community level. This exhibition can be visited at the Hospital Clínic of Barcelona until February 2018.

    Read the rest of this entry

  • October 26, 2017

    Computational Simulations Suggest Multiple Sclerosis is a Single Disease

    IDIBAPS researchers publish a study in the journal Plos Computational Biology that supports the idea that multiple sclerosis (MS), which has widely varying symptoms and progression in different patients, is nonetheless a single disease with common underlying mechanisms. Pablo Villoslada, Head of the IDIBAPS group Pathogenesis and new treatments in Multiple Sclerosis, has coordinated the study. Ekaterina Kotelnikova, researcher at the same group, is the first author.

    Read the rest of this entry

  • October 18, 2017

    Gisela Sugranyes awarded with a NARSAD Young Investigator Grant

    The Brain and Behaviour Research Foundation has awarded a research grant to Gisela Sugranyes, 50/50 researcher at the Multimodal neuroimaging in high risk and early psychosis IDIBAPS research team. The 'NARSAD 2017 Young Investigator Grant' is endowed with 70,000 for two years and is one of the most prestigious awards given to young researchers in the field of neuroscience. In this case, the funds will be used in the study of psychosis, specifically in determining the role played by an alteration in glutamatergic transmission in the clinical and cognitive manifestations of the disorder.

    Read the rest of this entry

  • October 9, 2017

    IDIBAPS researchers describe the mechanism by which SOX11 promotes relapses in mantle cell lymphoma

    Researchers at IDIBAPS publish an article in the Blood journal in which they show the mechanism by which the transcription factor SOX11 participates in the dissemination and aggressiveness of mantle cell lymphoma. They have discovered that SOX11 promotes the creation of a protective environment that ensures survival and resistance to treatments of tumor cells. The study was coordinated by Dr. Virginia Amador, researcher at the Human and experimental functional oncomorphology IDIBAPS team.

    Read the rest of this entry

  • June 12, 2017

    Aleix Prat, named Board Member of the Breast International Group

    Dr. Aleix Prat, Head of the Clinical Oncology Department at Hospital Clínic and of the Translational genomics and targeted therapeutics in solid tumors research team at IDIBAPS, has been named member of the Executive Board of the Breast International Group (BIG). The BIG is an international non-profit organisation that includes more than 56 cooperative groups from around the world, more than 10,000 experts and it is linked to more than 3,000 hospitals. Its main goal is to promote clinical and translational research in breast cancer. The appointment, which represents a recognition to his professional career in this field, took place during the annual meeting of the American Society of Clinical Oncology (ASCO) held in June 2-6 in Chicago.

    Read the rest of this entry